Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
KISUNLA Konz Inf 350 mg 1 Stk
Drug
Kisunla, Konzentrat zur Herstellung einer Infusionslösung
01.99.0. – various
HAM – Human medicine
KOINF – Concentrate for solution for infusion
BT – biological medicines
A – Dispensed once only on prescription by a physician or veterinarian (A)
Z – approved
1/22/2026
1/21/2031
Dosage strength
Kisunla 350 mg, Konzentrat zur Herstellung einer Infusionslösung
Leichte kognitive Störung oder leichte Demenz vom Alzheimer Typ mit nachgewiesener Alzheimer-typischer Amyloid-beta Pathologie bei heterozygoten Trägern oder Nicht-Trägern von Apolipoprotein E ε4 (ApoE ε4)
01
Z – approved
Package
7680695230017
In trade from / since 2/25/2026
A/R – Authorised / referenced
1 vial(s)
001
Z – approved
Declaration
Component
350 mg donanemabum
natrii citras dihydricus
acidum citricum
saccharum
polysorbatum 80
aqua ad iniectabile
11.5 mg natrium
acidum citricum
saccharum
polysorbatum 80
aqua ad iniectabile
11.5 mg natrium
Authorisation holder
7601001261853
Eli Lilly (Suisse) SA
chemin des Coquelicots 16
580
1214 Vernier (GE)
chemin des Coquelicots 16
580
1214 Vernier (GE)
Date of revision of the text
2/25/2026
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.